Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience

Objective: The aim of this study is to determine safety and feasibility of conscious sedation using dexmedetomidine for transcatheter atrial septal defect (ASD) device closure. Material and Methods: A retrospective institutional review of transcatheter ASD device closure without endotracheal intubat...

Full description

Bibliographic Details
Main Authors: Pushkar Mahendra Desai, Sanjeeta R Umbarkar, Manjula S Sarkar, Rishi Lohiya
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Annals of Cardiac Anaesthesia
Subjects:
Online Access:http://www.annals.in/article.asp?issn=0971-9784;year=2016;volume=19;issue=3;spage=463;epage=467;aulast=Desai
id doaj-13800386d66142c3b56021f4cc01c105
record_format Article
spelling doaj-13800386d66142c3b56021f4cc01c1052020-11-25T02:29:19ZengWolters Kluwer Medknow PublicationsAnnals of Cardiac Anaesthesia0971-97842016-01-0119346346710.4103/0971-9784.185528Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experiencePushkar Mahendra DesaiSanjeeta R UmbarkarManjula S SarkarRishi LohiyaObjective: The aim of this study is to determine safety and feasibility of conscious sedation using dexmedetomidine for transcatheter atrial septal defect (ASD) device closure. Material and Methods: A retrospective institutional review of transcatheter ASD device closure without endotracheal intubation over 18 months. The protocol included topical oropharyngeal anesthesia using lignocaine followed by dexmedetomidine bolus 1 μg/kg intravenously over 10 min and maintenance dose 0.2-0.7 μg/kg/h. Ramsay sedation score 2-3 was maintained. Patients were analyzed regarding demographic profile, device size, procedure time, anesthesia time, recovery time, hospital stay, and any hemodynamic or procedural complications. Results: A total of 43 patients with mean age 31.56 ± 13.74 years (range: 12-56 years) were analyzed. Mean anesthesia duration was 71.75 + 21.08 min. Mean recovery time was 7.6 ± 3.01 min. 16 females and one male patient required additional propofol with a mean dose of 30.8 ± 10.49 mg. No hemodynamic instability was noted. No patient required general anesthesia with endotracheal intubation. The procedure was successful in 93.02% of patients. Four patients developed atrial fibrillation. All patients were satisfied. Conclusion: Conscious sedation using dexmedetomidine is a safe and effective anesthetic technique for percutaneous ASD closure.http://www.annals.in/article.asp?issn=0971-9784;year=2016;volume=19;issue=3;spage=463;epage=467;aulast=DesaiAmplatzer device; Atrial septal defect; Dexmedetomidine; Sedation; Transcatheter
collection DOAJ
language English
format Article
sources DOAJ
author Pushkar Mahendra Desai
Sanjeeta R Umbarkar
Manjula S Sarkar
Rishi Lohiya
spellingShingle Pushkar Mahendra Desai
Sanjeeta R Umbarkar
Manjula S Sarkar
Rishi Lohiya
Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
Annals of Cardiac Anaesthesia
Amplatzer device; Atrial septal defect; Dexmedetomidine; Sedation; Transcatheter
author_facet Pushkar Mahendra Desai
Sanjeeta R Umbarkar
Manjula S Sarkar
Rishi Lohiya
author_sort Pushkar Mahendra Desai
title Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
title_short Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
title_full Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
title_fullStr Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
title_full_unstemmed Conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: A single center experience
title_sort conscious sedation using dexmedetomidine for percutaneous transcatheter closure of atrial septal defects: a single center experience
publisher Wolters Kluwer Medknow Publications
series Annals of Cardiac Anaesthesia
issn 0971-9784
publishDate 2016-01-01
description Objective: The aim of this study is to determine safety and feasibility of conscious sedation using dexmedetomidine for transcatheter atrial septal defect (ASD) device closure. Material and Methods: A retrospective institutional review of transcatheter ASD device closure without endotracheal intubation over 18 months. The protocol included topical oropharyngeal anesthesia using lignocaine followed by dexmedetomidine bolus 1 μg/kg intravenously over 10 min and maintenance dose 0.2-0.7 μg/kg/h. Ramsay sedation score 2-3 was maintained. Patients were analyzed regarding demographic profile, device size, procedure time, anesthesia time, recovery time, hospital stay, and any hemodynamic or procedural complications. Results: A total of 43 patients with mean age 31.56 ± 13.74 years (range: 12-56 years) were analyzed. Mean anesthesia duration was 71.75 + 21.08 min. Mean recovery time was 7.6 ± 3.01 min. 16 females and one male patient required additional propofol with a mean dose of 30.8 ± 10.49 mg. No hemodynamic instability was noted. No patient required general anesthesia with endotracheal intubation. The procedure was successful in 93.02% of patients. Four patients developed atrial fibrillation. All patients were satisfied. Conclusion: Conscious sedation using dexmedetomidine is a safe and effective anesthetic technique for percutaneous ASD closure.
topic Amplatzer device; Atrial septal defect; Dexmedetomidine; Sedation; Transcatheter
url http://www.annals.in/article.asp?issn=0971-9784;year=2016;volume=19;issue=3;spage=463;epage=467;aulast=Desai
work_keys_str_mv AT pushkarmahendradesai conscioussedationusingdexmedetomidineforpercutaneoustranscatheterclosureofatrialseptaldefectsasinglecenterexperience
AT sanjeetarumbarkar conscioussedationusingdexmedetomidineforpercutaneoustranscatheterclosureofatrialseptaldefectsasinglecenterexperience
AT manjulassarkar conscioussedationusingdexmedetomidineforpercutaneoustranscatheterclosureofatrialseptaldefectsasinglecenterexperience
AT rishilohiya conscioussedationusingdexmedetomidineforpercutaneoustranscatheterclosureofatrialseptaldefectsasinglecenterexperience
_version_ 1724833731945955328